A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

Inclusion Criteria:

• Diagnosis of SLE according to the 2019 European League Against Rheumatism/AmericanCollege of Rheumatology (EULAR/ACR) Classification Criteria >=12 weeks prior toscreening

• Anti-nuclear antibody (ANA) >=1:80, or anti-dsDNA and/or anti-Sm antibodies abovethe upper limit of normal (ULN), as determined by the central laboratory atscreening

• Low C3 or low C4 or low CH50 complement as determined by the central laboratory atscreening

• High disease activity at screening, based on; BILAG-2004 (Category A disease in >=1organ system and/or Category B disease in >=2 organ systems), Systemic LupusErythematosus Disease Activity Index 2000 (SLEDAI-2K) (score >=8) and Physician'sGlobal Assessment (PGA) (score >=1.0 on a 0 to 3 visual analogue scale [VAS])

• High disease activity on Day 1, based on; SLEDAI-2K (score >=8) and PGA (score >=1.0on a 0 to 3 VAS)

• Current receipt of >=1 of the following classes of standard therapies for thetreatment of SLE at stable doses: oral corticosteroid (OCS), antimalarials,conventional immunosuppressants

• Other inclusion criteria may apply

• The Medical Monitor may be consulted if there are any questions related toeligibility criteria

Exclusion Criteria:

• Pregnancy or breastfeeding

• Presence of significant lupus-associated renal disease and/or renal impairment

• Receipt of an excluded therapy, including any anti-CD20, anti-CD19 therapy less than 9 months prior to screening or during screening; or cyclophosphamide, tacrolimus,ciclosporin, or voclosporin during the 2 months prior to screening or duringscreening

• Significant or uncontrolled medical disease which, in the investigator's opinion,would preclude patient participation

• Known active infection of any kind or recent major episode of infection

• Intolerance or contraindication to study therapies

• Other exclusion criteria may apply